Navigation Links
Novartis Drug Afinitor® Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial
Date:9/23/2011

orted more commonly in the placebo arm. During the study, one death in the everolimus arm occurred due to convulsion, though it was not considered related to the study drug by the investigator(1).

EXIST-2 enrolled 118 patients in the US, Germany, the Netherlands, Japan, the UK, Russia, Italy, Canada, Poland, Spain and France. This study is part of a Phase III trial program investigating everolimus in the various manifestations of TSC(1,10).

About everolimusIn the US, Afinitor® (everolimus) tablets is approved to treat patients with SEGA associated with TS who require therapeutic intervention but are not candidates for curative surgical resection. The effectiveness of everolimus is based on an analysis of change in SEGA volume. Clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been shown.

Afinitor is also approved in the US for the treatment of patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib and for the treatment of progressive neuroendocrine tumors of pancreatic origin (pNET) in patients with unresectable, locally advanced or metastatic disease. The US Food and Drug Administration (FDA) determined that the safety and effectiveness of Afinitor in the treatment of patients with carcinoid tumors have not been established.

In the US, everolimus is available from Novartis in different dosage strengths and for different uses in non-oncology patient populations under the trade name Zortress®. Everolimus is exclusively licensed to Abbott and sublicensed to Boston Scientific for use in drug-eluting stents.

Not all indications are available in every country. Access to everolimus outside of the approved indications has been carefully controlled and monitored in clinical trials designed to better understand the potential benefits and risks of the compound. As an investigational compound, the safety and efficacy profile o
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
2. Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
3. Novartis Drug Gleevec® Shows Significant Overall Survival Benefit for Patients With GIST After Three Years of Adjuvant Treatment vs. One Year
4. Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
5. Novartis Data Shows ACZ885 for Severe Gouty Arthritis Provided Better Pain Relief and Reduced Risk of New Attacks by Up to 68% vs. Steroid
6. FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors
7. Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET
8. Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin
9. US Supreme Court Denies Certiorari and Thereby Leaves in Place Second Circuit Ruling That Novartis Pharmaceuticals Corporation Must Pay its Sales Representatives Overtime Compensation
10. Novartis Gains FDA Approval for Amturnide™, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications
11. Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... 2013 Attorney Advertising -- Bronstein, Gewirtz & ... of purchasers of the securities of AMAG Pharmaceuticals, ... The investigation focuses on whether the Company and ... On May 22, 2013, Shares of AMAG dropped ... company announced in regulatory filing that it has ...
(Date:5/22/2013)... and MUNICH , May 22, 2013 /PRNewswire/ ... marketer of transcatheter aortic valve implantation (TAVI) systems for the ... results of the J enaValve Eval U ation of ... Pa T ients with S E vere Ao R tic ... . JUPITER is a post-market registry to evaluate five-year long ...
(Date:5/22/2013)... May 22, 2013 The new 13-valent pneumococcal ... the previous version used prior to 2010, the 7-valent ... study published today in Vaccine. The U.S. ... in 2010 after a series of trials. These trials ... of pneumococcal types than the previously used PCV7, did ...
Breaking Medicine Technology:Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals, Inc. 2First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System 2First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System 3First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System 4Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 2Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 3Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 4
... Progen,Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) today announced ... PI-88 as an adjuvant,treatment for primary liver cancer ... patient having been randomized,onto the study. The study ... treatment of HCC). The first patient to enter ...
... SILVER SPRING, Md., March 11 In a boost ... to provide a,royalty-free license to the non-profit International Partnership ... use as a,potential vaginal microbicide., The compound, called ... known as gp41 fusion inhibitors, which inhibit HIV infection ...
Cached Medicine Technology:Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer 2Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer 3Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer 4Microbicide Developer Receives License for Novel HIV Microbicide Candidate From Merck & Co., Inc. 2Microbicide Developer Receives License for Novel HIV Microbicide Candidate From Merck & Co., Inc. 3
(Date:5/22/2013)... On a Saturday morning last summer, MSgt. Joe DesLauriers ... Bourne Legacy” at the White Flint Mall movie theater in ... activity to many couples, it is a pure luxury for ... everyday reality has become possible through the Military Family Respite ... , Life changed for the DesLauriers family on Sept. 23, ...
(Date:5/22/2013)... York, New York (PRWEB) May 22, 2013 ... the nation’s first trial involving a da Vinci lawsuit, ... the case, the family of a man who allegedly died ... seeking more than $8 million in damages from Intuitive Surgical, ... down its physician training program for the da Vinci Surgical ...
(Date:5/22/2013)... Nearly 50,000 veterans appeals were received ... year 2012, with even more—54,033—expected by fiscal year-end 2013. ... decision as the agency reports reduced decisions and a ... disability appeal services. The BVA is an agency ... the BVA received 49,611 cases in FY 2012, it ...
(Date:5/22/2013)... CORVALLIS, Ore. A new study shows there is ... self-control in American young children one that does ... In the United States, girls had higher levels of ... to control their behavior and impulses, follow directions, and ... academic performance and college completion, in past studies by ...
(Date:5/22/2013)... May 22, 2013 Successful Therapy ... Patricia O’Laughlin Psychotherapy in the Silver Lake community ... all ages as progression to existing Parents and ... ages into parenting therapy has always been suggested, ... O’Laughlin Psychotherapy now specializes in all aspects of ...
Breaking Medicine News(10 mins):Health News:Military Family Finds Respite with Easter Seals 2Health News:Military Family Finds Respite with Easter Seals 3Health News:Da Vinci Robot Lawsuits: Bernstein Liebhard LLP Notes Beginning of Jury Deliberations in Nation’s First Trial Involving Alleged Da Vinci Surgery Complications 2Health News:Da Vinci Robot Lawsuits: Bernstein Liebhard LLP Notes Beginning of Jury Deliberations in Nation’s First Trial Involving Alleged Da Vinci Surgery Complications 3Health News:Da Vinci Robot Lawsuits: Bernstein Liebhard LLP Notes Beginning of Jury Deliberations in Nation’s First Trial Involving Alleged Da Vinci Surgery Complications 4Health News:Veterans Disability Appeals See Fewer Decisions in FY2012, Reports Allsup 2Health News:'Boys will be boys' in US, but not in Asia 2Health News:'Boys will be boys' in US, but not in Asia 3Health News:Patricia O’Laughlin Psychotherapy of Los Angeles Now Seeing Adults, Teens and Young Children 2
... 28, 2008 -- WASHINGTON, DC) The American ... Foundation (CRF) announced today a multi-year partnership to ... in Orlando, Fla., March 2831, 2009, during ACC.09, ... worlds premier cardiovascular meeting. This will be ...
... Wins First Canadian Golf Tour Title While Wearing Surgex(TM) Branded ... ... virus and a late bogey to capture his first Canadian Tour title,at the ... victory places the former University of Texas standout in prime,position to qualify for ...
... acid molecules fabricated in the laboratory have been shown ... 1 diabetes in animal models. The results of these ... G. Rangos Sr. Research Center at Childrens Hospital of ... a research study at Childrens Hospital, the scientists injected ...
... ("DRAXIS"),(TSX: DAX) (NASDAQ: DRAX ) announced today the ... common shares have been acquired by,an indirect wholly-owned subsidiary ... a result, DRAXIS common stock is expected to cease,trading ... Stock Exchange at,market close on Thursday, May 29, 2008, ...
... in the May 28, 2008 edition of The Journal ... action of certain brain cells altered by chronic alcohol ... the central amygdala, which plays an important role in ... alcohol drinking. In the study, alcohol-dependent rodents receiving gabapentin ...
... being,issued by the National Academy of Social Insurance:, ... 3:30 pm Seminar: Growing Risks for Workers and Growing ... from Behavioral Economics to Control Health Costs, Peter ... Benefits, Stephen C. Goss, Chief Actuary of the ...
Cached Medicine News:Health News:ACC and CRF announce partnership on ACC's Innovation in Intervention: i2 Summit 2Health News:Surgex(TM) Fuels 2008 San Luis Potosi Open Champion Russell Surber Through Grueling 36 Hole Final Day 2Health News:Surgex(TM) Fuels 2008 San Luis Potosi Open Champion Russell Surber Through Grueling 36 Hole Final Day 3Health News:New vaccine approach prevents/reverses diabetes in lab study at Children's Hospital of Pittsburgh 2Health News:New vaccine approach prevents/reverses diabetes in lab study at Children's Hospital of Pittsburgh 3Health News:DRAXIS Announces Completion of Sale to Jubilant 2Health News:DRAXIS Announces Completion of Sale to Jubilant 3Health News:DRAXIS Announces Completion of Sale to Jubilant 4Health News:Scripps Research scientists find seizure drug reverses cellular effects 2
Used where access is required into superior meniscal flap region....
This family of punches offers the best of both worlds the lowest profile and the largest bite, facilitating end-on and lateral cutting the most versatile instrument available....
The narrow shaft and compact jaw design facilitates access and use in tight spaces, particularly useful in the posterior aspect of the knee....
... Hand Instruments were developed in surgeon's desire ... still having an instrument with the strength ... fear of the bending or breaking. Arthrotek ... to conform to the surgeon's hand. This ...
Medicine Products: